Dr Reddys Laboratories Ltd
Unaudited Financial results for the quarter ended June 30, 2026
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 22 Jul 2026, 04:23 PM IST · BSE ID: 6abc2561-042f-4aef-849b-ecd22b9ef85e
View Original BSE Filing (PDF)
💡
In Simple Terms
Dr. Reddy's Q1 FY27 profit dropped to INR 4,348 million with a revenue decline, and a new Biologics head was appointed.
🤖 AI Summary
- Unaudited consolidated profit for the quarter ended June 30, 2026, was INR 4,348 million.
- Revenues for Q1 FY27 stood at INR 80,705 million, a 5.55% decrease from Q1 FY26.
- Dr. Sridevi Khambhampaty was appointed as Global Head of Biologics, effective July 22, 2026.
- M/s Deloitte Haskins & Sells, LLP, was approved as Independent Registered Public Accounting Firm for U.S. SEC filings.
- A provision of Rs. 2,397 million was made towards inventory and associated costs due to Semaglutide out-of-specification batches.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenues
80,705 INR Million
-5.55%
Profit for the period/year
4,348 INR Million
-69.15%
Basic earnings per share
5.32 Re. I/-each
-68.89%
Provision for Semaglutide
2,397 INR million
🏢 How This Affects the Company
The appointment of a Global Head of Biologics strengthens focus on this segment. Revenue decline in Q1 FY27 indicates a shift from prior year performance in Global Generics.
Consolidated profit for the quarter significantly decreased to INR 4,348 million from INR 14,096 million in Q1 FY26. A provision of Rs. 2,397 million impacted profitability due to product quality issues.
The provision for Semaglutide inventory costs signals an operational issue related to active pharmaceutical ingredient quality. The appointment of a new auditor for US SEC filings streamlines financial oversight.
The provision of Rs. 2,397 million for Semaglutide inventory and associated costs highlights a product quality and supply chain risk. The company continues to monitor geopolitical uncertainties.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results and appointment filing.
👤
Who Is Affected
All equity shareholders are affected by the company's financial performance, specifically the decline in profit for the period attributable to equity holders to INR 4,435 million.
🔍
Management Signal
Management is addressing strategic segment growth through key appointments and reinforcing financial governance with the appointment of a new Independent Registered Public Accounting Firm.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 unaudited financial results — assess revenue and profit trends.
Shareholder approval for Deloitte Haskins & Sells at the ensuing AGM.
Updates on the Semaglutide product issue and associated costs.
MEDIUM RISK
Significant drop in Q1 FY27 profit and revenue, partly due to a product quality provision.
💡 Investor Takeaway
Dr. Reddy's reported Q1 FY27 consolidated profit of INR 4,348 million, a 69.15% year-on-year decrease from INR 14,096 million in Q1 FY26. Revenues for the quarter were INR 80,705 million, down 5.55% from INR 85,452 million in Q1 FY26. A Rs. 2,397 million provision for Semaglutide inventory was recorded.
⚖️ Strengths & Concerns
✅ Positives
- Appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics indicates strategic focus on this growth area effective July 22, 2026.
- Approval of M/s Deloitte Haskins & Sells, LLP, as Independent Registered Public Accounting Firm for US SEC filings aligns auditing practices.
⚠️ Concerns
- Consolidated profit for the quarter ended June 30, 2026, decreased by 69.15% year-on-year to INR 4,348 million.
- Revenues for the quarter ended June 30, 2026, fell by 5.55% year-on-year to INR 80,705 million.
📅 Company Track Record
Dr. Reddy's FY26 profit for the year ended March 31, 2026, fell to INR 42,466 million, down from INR 54,817 million profit before tax. A dividend of INR 8/- per share was recommended in the May 12, 2026 filing.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Dr. Reddy's consolidated profit for the quarter ended June 30, 2026?
Dr. Reddy's consolidated profit for the quarter ended June 30, 2026, was INR 4,348 million.
What were Dr. Reddy's total revenues for the quarter ended June 30, 2026?
Dr. Reddy's reported total revenues of INR 80,705 million for the quarter ended June 30, 2026.
What was the year-on-year change in Dr. Reddy's consolidated profit for Q1 FY27?
The consolidated profit for Q1 FY27 (June 30, 2026) was INR 4,348 million, representing a 69.15% decrease from INR 14,096 million in Q1 FY26 (June 30, 2025).
Who was appointed as Global Head of Biologics at Dr. Reddy's?
Dr. Sridevi Khambhampaty was appointed as Global Head of Biologics and Senior Management Personnel of Dr. Reddy's Laboratories, effective July 22, 2026.
What provision did Dr. Reddy's make in Q1 FY27 for Semaglutide?
Dr. Reddy's made a provision of Rs. 2,397 million towards inventory and other associated costs during Q1 FY27 due to an issue with Semaglutide batches.
Questions based on this BSE filing only. For information purposes.